UNSPSC 51171654: Sulisatin sodium

This classification denotes a laxative C21H15NO9S2.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7S636L78GU, chemically known as 2h-indol-2-one, 1,3-dihydro-7-methyl-3,3-bis(4-(sulfooxy)phenyl)-, sodium salt (1:2), but more generally known as sulisatin sodium, which bears US NIH Compound Identifier 41237. European Medicines Agency schedules Sulisatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04641MIG.

Most nations, for tariff and trade purposes, schedule sulisatin sodium under HS 29337900 and SITC 51561. As of Q4 2014, SULISATIN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1CCCC2C1NC(=O)C2(C3CCC(CC3)OS(=O)(=O)[O-])C4CCC(CC4)OS(=O)(=O)[O-].[NA+].[NA+].

UNSPSC 51171654 Sulisatin sodium is a Commodity code that shows minimal alignment with recent state and local procurement activity. The three most recent opportunities tagged under this code involve offender drug testing services, pharmacy benefit program strategy, and generic pharmaceutical distribution through a multistate cooperative—none of which directly concern sulisatin sodium or the specific pharmaceutical products typically associated with this narrow commodity designation. Collin County Community Supervision and Corrections Department's RFP for offender specimen collection and drug testing services ($600,000, two-year term commencing September 1, 2026) and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (effective July 1, 2026) both address pharmaceutical procurement broadly, but neither solicitation references sulisatin sodium as a required or available product line. The Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescriptions is exploratory in nature and does not specify pharmaceutical products.

State issuing bodies driving activity tagged under this code include county criminal-justice agencies, state health and human services departments, and cooperative purchasing alliances serving multistate jurisdictions. The geographic footprint of recent opportunities spans Texas (Collin County, Texas HHS Commission) and Minnesota (MMCAP), with Oregon participation in the cooperative. Given the mismatch between the code's narrow commodity scope and the broad pharmaceutical-services activity in the recent opportunities block, the code appears either miscoded in source systems or underutilized for sulisatin sodium procurement at the state and local level. Practitioners should verify actual procurement intent directly with issuing bodies rather than relying on this code as a reliable signal for sulisatin sodium demand.